Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: August 05, 2026
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: February 16, 2026
Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors.
Journal: Eye (London, England)
Published: August 21, 2025
Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy.
Journal: Clinical genitourinary cancer
Published: May 13, 2025
From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma.
Journal: JCO oncology practice
Published: April 09, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
Journal: The oncologist
Published: February 04, 2025
Medical Professionals' Perceptions of and Experiences With Terminally Ill Orthodox Jewish Patients.
Journal: The American journal of hospice & palliative care
Published: January 04, 2025
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials.
Journal: Journal of kidney cancer and VHL
Published: June 04, 2024
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
Journal: Clinical genitourinary cancer
Published: June 04, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Journal: Journal for immunotherapy of cancer
Published: March 11, 2024
Last Updated: 09/26/2026